Patents
Literature
49 results about "E6 protein" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
E6 is present at extremely low levels in transformed cells, and no cellular homolog of E6 has been found. A small number of PVs—BPV-3, BPV-4, BPV-6—do not possess an E6 [20]. The E6 protein is a basic nuclear and cytoplasmic protein of about 18 kDa [21].
Antibodies for oncogenic strains of HPV and methods of their use
The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.
Owner:ARBOR VITA CORP
Antibodies for oncogenic strains of HPV and methods of their use
Owner:ARBOR VITA CORP
Methods of diagnosing cervical cancer
The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.
Owner:ARBOR VITA CORP
Antigen epitope minimum motif peptide of human papilloma virus 58 type E6 protein
The invention belongs to the technical field of biological medicine and biological detection and particularly relates to antigen epitope minimum motif peptide of a human papilloma virus (HPV) 58 type E6 protein and an application thereof. The invention provides four epitope peptides (comprising an 8-peptide sequence which can be expressed in a fusion way with carrier proteins such as truncated GST188 and the like and contain epitope minimum motif) which can be used as antigens for specifically detecting HPV 58 type virus infection in a single way or a combination way and contains the minimum motif and a marker minimum motif peptide amino acid sequence used for specifically detecting low risk type HPV virus infection and medium-high risk type HPV virus infection in a discrimination way. The amino acid sequences of the minimum motif peptides and short peptides are shown as SEQ ID No.1-SEQ ID No.9.
Owner:GUANGDONG NANWAN PHARMA TECH CO LTD +1
HPV6 type l2n120e7e6 fusion protein gene, expression vector, method, bacterial strain and application
The invention provides a gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, a method, a bacteria strain and an application. The invention is characterized in that prokaryotic expression vectors are utilized to fuse HPV 6-type L2N-end 120 amino acids, E7 proteins and E6 proteins, and constructing the encoded gene according to the amino acid of the fusion protein. In the invention, the gene for encoding the HPV 6-type L2N120E7E6 fusion proteins is successfully designed and the expression vectors and the transformation bacteria strain of the high-expression HPV 6-type L2N120E7E6 fusion proteins are successfully constructed; and in the fusion proteins, the immunogenicity is strong, the immunoreaction of specific T cells can be induced, the tumor forming time of mice can be obviously delayed, and the growth of the tumors of 20% mice is completely restrained. The invention can be used for preventing and treating HPV 6-type infection and relevant diseases, such as genital wart.
Owner:中国疾病预防控制中心病毒病预防控制所
HPV18 type L2NE7E6 fusion protein gene, and expression vector, preparation method, strain and use thereof
ActiveCN103864936AImproving immunogenicityShorten the formation timeBacteriaViral antigen ingredientsDiseaseEscherichia coli
The invention provides a human papilloma virus (HPV) 18 type L2NE7E6 fusion protein gene efficiently expressing in Escherichia coli, and an expression vector, a preparation method, a strain and a use thereof L2N protein, E7 protein and E6 protein amino acid sequences of 11th-200th amino acids of an HPV18 type L2 protein are fused, a codon optimization gene suitable for Escherichia coli expression is designed, the codon optimization gene is inserted into a prokaryotic expression vector pET9a to obtain a pET9a-HPV18L2NE7E6 expression vector and its conversion strain, the expression level accounts for 50% of all bacteria, an antibody generated by a pure fusion protein immune mouse can neutralize an HPV18 type pseudovirus in order to generate a specific T cell immune response and obviously postpone the tumor formation time of the mouse, and the growth of 20% of mouse tumors can be completely inhibited. The fusion protein can be used for developing vaccines for preventing and treating HPV18 type infection and relevant diseases.
Owner:中国疾病预防控制中心病毒病预防控制所
Methods of diagnosing cervical cancer
The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.
Owner:ARBOR VITA CORP
HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and construction method thereof
InactiveCN102228698APreserve antigenicityGood antigenicityViral antigen ingredientsGenetic material ingredientsGlycineE6 protein
The invention discloses an HPV58 (Human Papilloma Virus) type therapeutic composite genetic vaccine and a construction method thereof. In the vaccine, an HPV58 type E6 / E7 fusion gene is used as a target antigen, and GM / B7 is used as an antigen adjuvant, wherein stop codes of HPV58 type E6 and E7 genes are removed from the HPV58 type E6 / E7 fusion gene; and meanwhile, amino acids of 50, 63 and 106 on E6 protein and the amino acids 24, 26 and 92 on E7 protein are mutated into glycines. The HPV58 type therapeutic composite genetic vaccine provided by the invention has high safety, strong immunity and an ideal anti-tumor effect, provides a better choice for treating cervical carcinoma and precancerous lesion related to the HPV58 type infection, and is particularly suitable for HPV58 type highly-infective cervical carcinoma patients in China and Asia.
Owner:广西医科大学附属肿瘤医院
Detection of Human Papillomavirus
InactiveUS20070292841A1Avoid developmentUnstable cell activity/genomeMicrobiological testing/measurementE6 proteinHigh-Grade Squamous Intraepithelial Lesions
The present invention relates to in vitro methods of screening human subjects for the presence of human papillomavirus (HPV) which exhibits loss of regulation of E6 / E7 mRNA expression and loss of replication and / or expression of a stabilized pre-mRNA encoding full length E6 protein. In particular, the invention provides in vitro methods of screening for persistent cell abnormalities or persistent CIN III lesions, cancer in situ or high-grade squamous intraepithelial lesions (HSIL). The methods are useful in the context of cervical cancer screening.
Owner:NORCHIP AS
HPV E6 protein T cell epitopes and uses thereof
ActiveUS8652482B2Preventing and treating pathophysiological conditionBiocideViral antigen ingredientsE6 proteinWhite blood cell
Owner:BIOVENTURES LLC
HPV E6 protein T cell epitopes and uses thereof
ActiveUS20110293651A1Avoid adjustmentImprove lesionViral antigen ingredientsMicrobiological testing/measurementE6 proteinWhite blood cell
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.
Owner:BIOVENTURES LLC
Medicine for treating HPV (human papillomavirus) infection and application thereof
ActiveCN109055376AReduced expression levelPrevent proliferationOrganic active ingredientsHydrolasesE6 proteinTarget mrna
The invention discloses a medicine for treating HPV (human papillomavirus) infection and application thereof. A sequence of crRNA (crispr-derived ribonucleic acid) for targeting mRNA (messenger ribonucleic acid) for editing human papillomavirus E6 protein is shown in SEQ ID NO: 1 or SEQ ID NO:2. The designed crRNA can be used for constructing a Crispr / Cas13a system and can be used for treating theHPV infection.
Owner:THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV +1
HPV E6 protein T cell epitopes and uses thereof
ActiveUS20090136531A1Preventing and treating pathophysiological conditionOrganic active ingredientsBiocideE6 proteinWhite blood cell
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population.
Owner:BIOVENTURES LLC
Antibodies specific to e6 proteins of HPV and use thereof
InactiveUS20120141502A1High sensitivityHigh affinityPeptide librariesMicrobiological testing/measurementAntibodyE6 protein
The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.
Owner:ARBOR VITA CORP
HPV E6 protein T cell epitopes and uses thereof
ActiveUS8926961B2Preventing and treating pathophysiological conditionImprove lesionBiocideViral antigen ingredientsE6 proteinWhite blood cell
The present invention is directed to the examination of the pattern of immunodominant T cell epitopes in the E6 protein of Human Papilloma virus and its further characterization in terms of its amino acid sequence and Human Leukocyte Antigen restriction. These epitopes are identified based on their ability to induce specific T cell responses and therefore, are important as sources of antigens for immunotherapies to treat cervical and other cancers. The present invention contemplates identifying a number of similar epitopes restricted by a wide variety of Human Leukocyte Antigen types so that they can be used together to develop preventative or therapeutic vaccines, which can be used for the general human population. The present invention also contemplates using E6 peptides of Human Papilloma virus as a diagnosis method to predict the probability of developing persistent cervical neoplasia in an individual.
Owner:BIOVENTURES LLC
Application of Eu-containing polyoxometalate in in-vitro assay of early pathogenic protein E6 of human papillomavirus
The invention relates to application of Eu-containing polyoxometalate in the in-vitro assay of the early pathogenic protein E6 of human papillomavirus, which belongs to the technical field of assaying the early pathogenic protein E6 of human papillomavirus by means of polyoxometalate. The invention utilizes the strong recognition interaction between basic amino acid-rich small peptides on EuW10 and HPV E6 proteins to assay the HPV E6 protein. A research discovers that the E6 small peptide and protein can be assembled with EuW10 into spheres to promote the remarkable enhancement of fluorescence. The invention is the first example of utilizing polyoxometalate for in-vitro E6 protein assay. The polyoxometalate EuW10 synthesis method utilized by the invention is simple and easy to obtain. The assay method disclosed by the invention has the advantages of high assay speed, simplicity and convenience in operation, simple system, stable signals and high sensitivity, and does not need any pretreatment and a complex assay instrument. Through the invention, the application of polyoxometalate as a biological probe is expanded, which is of a great significance to the pre-cancer early assay of cervical cancer.
Owner:JILIN UNIV
Novel HPV therapeutic nucleic acid vaccine
ActiveCN114134165AInduced immunityInduce high immunityHydrolasesAntibody mimetics/scaffoldsAdjuvantAntiendomysial antibodies
The nucleic acid sequence provided by the invention comprises an HPV16-AVLS1 sequence and an HPV16-AVLC1 sequence in a ratio of 1: 1; the ratio of the HPV18-AVLS1 sequence to the HPV18-AVLC1 sequence is 1: 1; the sequence AVLS1 and the sequence AVLC1 respectively comprise two E6 proteins which are connected in series, two L1 short peptides, two L2 short peptides, two E7 proteins which are connected in series, a PADRE sequence and an adjuvant sequence; the N end of the sequence AVLS1 is provided with a mouse IgK secretory peptide sequence; the N end of the sequence AVLC1 is provided with a ubiquitin sequence. The nucleic acid sequence provided by the invention not only can induce a high-titer anti-E6 / E7 antibody, but also can induce high-level functional cellular immunity, and shows excellent effects of preventing and treating HPV-related tumors.
Owner:BEIJING AEONVITAL BIOMEDICINE RES CO LTD
Fusion albumen containing HSP70 ATPase structure field and mammal p53 albumen and application thereof
ActiveCN1919873AReduce adverse reactionsGood immune effectPeptide/protein ingredientsGenetic material ingredientsATPaseE6 protein
The invention discloses a framework area including human HSP70 ATPase and human papillomavirus E7, E6 protein or merge protein of mammalian p53 protein. The invention also discloses a pharmaceutical compound of merge protein, gene of encoding merge protein, the expressive carrier of merge protein and the usage of preparing medicine to treat or avoid tumor as human papillomavirus or tumor related to p53 protein overdose express.
Owner:BEIJING SUNBIO BIOTECH
Antibodies specific to e6 proteins of HPV and use thereof
InactiveUS20150153345A1High affinityHigh sensitivityPeptide librariesLibrary screeningE6 proteinAntibody
The subject invention provides an antibody composition for detecting E6 protein of at least one HPV strain in a sample. The subject antibodies may be used to detect oncogenic HPV E6 proteins in a sample, and the antibodies find use in a variety of diagnostic and therapeutic applications, including methods of diagnosing and treating cancer. Kits for performing the subject methods and containing the subject antibodies are also provided. Also disclosed in the present invention is a method of generating an antibody that specifically binds to amino-terminus of E6 proteins of at least two HPV strains.
Owner:ARBOR VITA CORP
A Novel HPV Therapeutic Nucleic Acid Vaccine
ActiveCN114134165BInduced immunityInduce high immunityHydrolasesAntibody mimetics/scaffoldsAdjuvantAntiendomysial antibodies
The nucleic acid sequence provided by the present invention includes a 1:1 HPV16-AVLS1 sequence and an HPV16-AVLC1 sequence; and a 1:1 HPV18-AVLS1 sequence and an HPV18-AVLC1 sequence; the sequence AVLS1 and the sequence AVLC1 respectively include two tandem E6 proteins , two L1 short peptides, two L2 short peptides, two tandem E7 proteins, a PADRE sequence and an adjuvant sequence; the N-terminal of the sequence AVLS1 has a mouse IgK secretory peptide sequence; the N-terminal of the sequence AVLC1 has a pan prime sequence. The nucleic acid sequence provided by the invention can not only induce high-titer anti-E6 / E7 antibodies, but also induce high-level functional cellular immunity, showing excellent effects of preventing and treating HPV-related tumors.
Owner:BEIJING AEONVITAL BIOMEDICINE RES CO LTD
Nanometer antibody for detecting HPV16 E6 protein and application thereof
HPV16 is a main cause of malignant tumors such as cervical cancer, and E6 protein of HPV16 becomes a key treatment and diagnosis target. In the prior art, an HPV16 detection antibody has the problems of poor stability, dependence on cold chain transportation, low preparation efficiency and the like. According to the invention, a nano antibody sequence which is high in affinity (dissociation constant KD is less than or equal to 1 * 10 <-7 > M) and stable at room temperature is obtained through total synthesis library construction and a phage-assisted directed evolution (PACE) screening technology. After the antibody is stored at 25 DEG C for 30 days, the activity of the antibody is kept to be greater than or equal to 95%, the antibody can be directly used for household test paper, the accuracy rate reaches 98%, and meanwhile, the antibody can be expanded to medical applications such as CAR-T cell therapy. Compared with a traditional antibody, the antibody has the advantages of being short in preparation period, low in cost, wide in application scene and the like, and a breakthrough solution is provided for early screening of cervical cancer.
Owner:BEIJING ZHIYUAN SHENLAN TECHNOLOGY CO LTD
Small molecule antiviral drug treatment for human papillomavirus infections
ActiveUS12583850B2Organic active ingredientsOrganic chemistryHuman papilloma virus infectionE6 protein
Owner:THE TRUSTEES OF INDIANA UNIV +1
Polypeptide with binding affinity to hpv18 e6 protein and application thereof
The present application provides a polypeptide with binding affinity to HPV18 E6 protein, taking the Z domain of staphylococcal protein A as a scaffold, randomly mutating the surface amino acid residues to simulate antibody binding sites, constructing a mutant library through phage display technology, screening the library through affinity with HPV18 E6 as a target antigen, and finally obtaining a polypeptide with high affinity to HPV18 E6 through a large number of screening work. Through in-depth research, the present application first discloses a polypeptide with binding affinity to the E6 protein of HPV18. In addition, the present application also provides the diagnostic or therapeutic use of the polypeptide as a drug or molecular targeting reagent.
Owner:WENZHOU MEDICAL UNIV
Application of an eu-containing polymetallic oxygen cluster in the detection of human papillomavirus early oncoprotein e6 in vitro
Owner:JILIN UNIV
E6 protein mutant serving as E3 ubiquitin ligase ligand and activating factor and application of E6 protein mutant
The invention discloses an E6 protein mutant serving as an E3 ubiquitin ligase ligand and an activating factor and application of the E6 protein mutant, and relates to the technical field of biological medicine. The amino acid sequence of the E6 protein mutant is as shown in SEQ ID NO. 1. According to the invention, E6 protein is modified to obtain an E6 protein mutant, and the E6 protein mutant is used as a novel E3 ubiquitin ligase ligand and an activating factor and is applied to construction of a protein degradation targeting chimera. Compared with the prior art, the invention provides a new tool for the PROTAC technology. The E6 protein mutant serving as an E3 ubiquitin ligase ligand and an activating factor can be combined with ubiquitin protein ligase UBE3A / E6AP in a targeted mode, and after the E6 protein mutant is combined with a target protein ligand of target protein, formed fusion protein can activate the ubiquitin protein ligase UBE3A / E6AP and efficiently degrade the target protein in a targeted mode.
Owner:SOUTHERN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Multiplex assay kit for cervical cancer precancerous lesion and cancerous lesion detection, preparation method therefor, and use thereof
A multiplex assay kit for cervical cancer precancerous lesion and cancerous lesion detection, a preparation method therefor, and the use thereof. The multiplex assay kit at least comprises multiple test strips for detecting the following indexes: the E5 protein, the E6 protein, the E7 protein, and hTERT. A connecting pad (2) of each test strip is coated with a detection antibody-colloidal gold conjugate, and a detection line (3) of the test strip is coated with a specific capture antibody, the specific capture antibodies on the test strips being different. The multiplex assay of the E5 protein, the E6 protein, the E7 protein, and hTERT can effectively improve the sensitivity and specificity of cervical cancer precancerous lesion and cancerous lesion detection. Compared to detection of only the E7 protein, the multiplex assay kit has significantly improved detection rate, sensitivity, and specificity.
Owner:MIAO JINCHAO
Fine epitope peptide capable of inducing cross-reactive antibodies among homologous proteins in human papilloma virus e6 protein
This invention relates to the minimal motif of an epitope on the E6 protein from human papilloma virus (HPV), and this minimal motif of the epitope induces a monoclonal antibody having cross-reactivity with some homologous proteins of HPVs. The inventors are the first to identify a fine antigenic epitope only existing conservatively on the E6 proteins of high risk HPV16, 33, 52 or 58). Therefore, the peptides comprising this epitope can be used to prepare immunogen or serological detection antigen against the HPV E6 proteins, or to prepare specific universal antibodies for a variety of high-risk / carcinogenic HPVs.
Owner:GUANGDONG NANWAN PHARMA TECH CO LTD +1
Mutant of HPV53 E6 protein and application thereof
The invention discloses a mutant of HPV53 E6 protein and application of the mutant. Compared with wild type E6, the mutant has the following three mutation sites: K79W, S133P and N8K, the K79W mutation design enhances the stability of a hydrophobic space and forms new hydrophobic interaction with Y108 / H130, S133P enables the flexibility of a loop region to be more stable, N8K mutation forms a salt bridge with E10 / E11, and the relation between the loop region and helix is enhanced. The mutation designs can maintain the stability of the whole structure, significantly improve the protein stability and immunogenicity, break through the technical bottlenecks of low in-vivo expression quantity and weak immunogenicity of the natural E6 protein, and provide a new way for immunotherapy of HPV53 related lesions.
Owner:HEFEI AFANA BIOTECHNOLOGY CO LTD
Detection of human papillomavirus
InactiveUS20100330550A1Microbiological testing/measurementE6 proteinHigh-Grade Squamous Intraepithelial Lesions
Owner:NORCHIP AS
Gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, method, bacteria strain and application
The invention provides a gene for encoding HPV (human papilloma virus) 6-type L2N120E7E6 fusion protein, expression vectors, a method, a bacteria strain and an application. The invention is characterized in that prokaryotic expression vectors are utilized to fuse HPV 6-type L2N-end 120 amino acids, E7 proteins and E6 proteins, and constructing the encoded gene according to the amino acid of the fusion protein. In the invention, the gene for encoding the HPV 6-type L2N120E7E6 fusion proteins is successfully designed and the expression vectors and the transformation bacteria strain of the high-expression HPV 6-type L2N120E7E6 fusion proteins are successfully constructed; and in the fusion proteins, the immunogenicity is strong, the immunoreaction of specific T cells can be induced, the tumor forming time of mice can be obviously delayed, and the growth of the tumors of 20% mice is completely restrained. The invention can be used for preventing and treating HPV 6-type infection and relevant diseases, such as genital wart.
Owner:STATION OF VIRUS PREVENTION & CONTROL CHINA DISEASES PREVENTION & CONTROL CENT